The Board of OneSource Specialty Pharma at its meeting held on 04 August 2025 has given their in-principle approval to evaluate potential acquisition of the Sterile Injectable CDMO and CMO businesses of Steriscience and Carbapenem facility of Brooks Steriscience.
The potential transaction, if finalised and consummated, will bring in the following facilities into OneSource:
- USFDA-approved sterile fill-finish manufacturing facility in Warsaw, Poland, with the ability to expand capacity for drug-device combination products for our global partners. This site serves marquee global players and several IP-led products. „h
- An integrated, state-of-the-art, USFDA-approved carbapenem facility in Vadodara, India operated under the name of Brooks Steriscience.
Steriscience SG and Brooks Steriscience Limited are majorly owned directly/ indirectly by the Promoters of the Company.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."